The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

The investment firm noted that recently released results from the Phase 1 Helios study of Axpaxli in non-proliferative diabetic retinopathy, or NPDR, showed no notable safety issues. It added that ...

OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops for patients with diabetic retinopathy (DR ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

Early poliferative diabetic retinopathy Neovascularization of the disc or elsewhere, which does not meet the high-risk characteristics High-risk proliferative diabetic retinopathy Moderate or ...